U.S. FDA Feb. 7 granted Ranbaxy a tentative approval for 20 mg and 40 mg delayed-release capsules of esomeprazole, a generic version of AstraZeneca's Nexium. The proton pump inhibitor is scheduled to lose U.S. exclusivity in October 2009. AstraZeneca reported $3.4 billion in U.S. Nexium sales for 2007. Gurgaon, India-based Ranbaxy claims it has first-to-file status for esomeprazole, which would give the company 180-day marketing exclusivity
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.